Hostname: page-component-5c6d5d7d68-wtssw Total loading time: 0 Render date: 2024-08-30T22:56:47.486Z Has data issue: false hasContentIssue false

Utilization of psychotropic drugs in Europe: Why is Portugal such a particular case?

Published online by Cambridge University Press:  23 March 2020

T. Alves-dos-Reis*
Affiliation:
Hospital do Espírito Santo de Évora, Psiquiatria e Saúde Mental, Évora, Portugal NOVA Medical School Faculdade Ciências Médicas, Mental Health, Lisbon, Portugal
M.A. Matias
Affiliation:
Nova School of Business and Economics, Universidade Nova de Lisboa, Business and Economics, Lisbon, Portugal
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Psychotropic drugs are among the most utilized medications in Europe.

Objectives

To perform an international comparison of the utilization trends of antidepressants, anxiolytics, hypnotics and sedatives (AHS).

Methods

We used data from the Organization for Economic Cooperation and Development (OECD). We used the World Health Organization's Defined Daily Dosage (DDD) per 1000 inhabitants per day (DHD) methodology. We performed a general comparison between 14 European countries and a more detailed comparative analysis between Portugal, Italy, Spain and Germany. These countries were selected according to the following criteria: similar 12-month prevalence of mental health disorders, similar results for negative mental health (SF-36 questionnaire) and similar standardized death rates for suicide.

Results

Portugal had the highest overall utilization of antidepressants and AHS in 2011, amounting to 110.7 DHD, and the highest increase in utilization of AHS (1.8%) from 2003 and 2011. Concerning antidepressants, Portugal had the third highest utilization of these drugs in 2011 (78.3 DHD). Regarding the more detailed comparative analysis, utilization of AHS was still significantly higher in Portugal. Considering antidepressants, Portugal experienced an increasing utilization, which grew by approximately 11.4% from 2003 and 2008. From 2009 onward the utilization increased but at a slower pace.

Conclusion

The very high utilization of these drugs, especially of AHS, is a worrying fact since this might indicate an inadequate treatment choice for anxiety and depressive disorders. Further research is needed to better understand the relationship of these findings with regulations concerning utilization of psychotropic drugs and compliance with best medical practices between distinct European countries.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EW439
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.